A2 Biotherapeutics is a clinical-stage, fully integrated discovery, development and manufacturing company based in Agoura Hills, Calif., founded in 2018. The company develops first-in-class logic-gated cell therapies using its Tmod™ platform, which combines an activator and a blocker receptor to target tumors while protecting normal tissues. A2 Bio is conducting two seamless phase 1/2 studies—EVEREST-1 (A2B530 targeting CEA) and EVEREST-2 (A2B694 targeting mesothelin)—with patient enrollment via the BASECAMP-1 AI-enabled prescreening study. The company plans to advance three clinical development programs and additional preclinical programs built on the Tmod™ platform. Management cited initial clinical data from lead programs as validation of the logic-gate approach. A recent $80 million Series C will fund ongoing clinical development and pipeline advancement. A2 Biotherapeutics develops Tmod-engineered T cells, a next-generation cell-therapy platform that pairs a potent activating mechanism with a blocking mechanism to selectively kill tumor cells that have lost specific genes while sparing normal cells. The company published proof-of-concept work in Molecular Immunology describing the Tmod dual-targeting system and its ability to recognize and selectively kill tumor cells that lost defined target molecules. A2 plans to advance three near-term product candidates built on the Tmod platform, with the first slated to begin clinical testing in 2022, and to extend the platform to produce additional candidates. Proceeds from its recent financing will also support the clinical development and operation of A2’s completed in-house cell-therapy manufacturing facility. The company was established in 2018, is based in Agoura Hills, California, and has more than 40 staff. A2 has raised $136M since inception and employs former Amgen and Kite Pharma developers on its team to advance discovery, development and manufacturing. A2 Biotherapeutics develops cell therapies that aim to selectively kill tumor cells while sparing normal tissue by leveraging rare antibody and T-cell receptor binders. The company combines a target binder discovery and optimization platform with proprietary cell engineering, modular vector designs, and novel quantitative assays to extend cell therapies into solid tumors. Its platform addresses two target classes: peptide‑MHC targets (to access intracellular neo‑antigens) and targets lost via loss of heterozygosity using modular cell engineering. A component of the platform, HuTARG™, is licensed from collaborator and co‑founder Innovative Targeting Solutions. The company was founded in 2018 and operates a fully integrated discovery, development, and manufacturing organization in Agoura Hills, California with a team of more than 40 staff. A2 Biotherapeutics expects its first clinical candidate next year and plans to launch an autologous cell manufacturing facility in 2020 with technology scalable for commercial launch.

Total raised

$209M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2025